Pharma’s new D2C sites can reduce barriers to care and treatment, but brands boost awareness of their platforms to drive adoption.
Unless Congress codifies drug pricing deals, TrumpRx risks serving more as political optics than a driver of meaningful patient affordability.
Doctors guide consumers’ clinical health decisions, but AI and influencers more often steer daily health habits.
The move could curb telehealth’s copycat obesity drugs and steer patients back to branded options.
Near-universal AI adoption in healthcare is approaching. Now organizations want their experiments to prove ROI.
Health benefits leaders often fail to inform workers about Rx savings options because opaque PBM contracts create confusion, driving the rise of more transparent, direct-to-employer pharma models.
It generated nearly $20 billion sales in Q1, led by GLP-1 brands Mounjaro and Zepbound, positioning it ahead of a pill rivalry with Novo.
The FDA is testing real-time data feeds in studies that could speed drug approval times but also changes how drug companies submit data for review.
Accelerated dealmaking hits $66 billion as big pharma players look to mitigate steep patent cliff losses and diversify pipelines.
Consumers value both AI and humans for health tasks but defer to humans for high-stakes guidance, meaning AI companies should position their tools as assistive rather than replacements for doctors.
93% make short- and long-term health changes from tracker data, outpacing older cohorts and redefining what effective apps must deliver.
Utah doctors are challenging the state’s AI plan for prescription refills, potentially deterring similar pilots and forcing AI companies to prove patient safety and gain physician support before launching experiments.
Millennials lead in online health purchases, but brands still need to compete with trusted reviews, active engagement, and clear value and convenience.
Waning consumer faith in traditional media and public health agencies means brands must turn to local doctors and creators to counter false health claims.
Close to 40% are familiar with the concept of healthspan and are actively building the foundation for healthier aging.
Regeneron caps Trump’s first deal wave with price cuts and US investment, but risks codifying federal pricing rules into law.
More physicians are using AI for clinical search, pushing tech companies to compete on speed, medical sourcing, and trust.
With insurers declining to participate in GLP-1 coverage, Medicare will now subsidize the drugs, though concerns around muscle loss may temper prescribing.
RFK Jr. backs voluntary limits for food marketing, aligning unhealthy food with pharma in Washington’s broader crackdown on health-linked marketing.
The anti-aging market isn’t fueled by broad, mass adoption. In reality, only about 10% of US consumers actively prioritize preventing signs of aging, according to YouGov’s 2026 Anti-aging report.